Fundraising Fox
/Companies
Sign in

Ilico Genetics

Santiago, CL · Founded 2020 · 5 employees on LinkedIn · 2 known investors

Find your way into Ilico Genetics

Sign up to see every warm intro you have to Ilico Genetics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Ilico Genetics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.

BiotechHealthtechMedical Devices

Founders & leadership

Ilico Genetics was founded in 2020 by Alejandro Corvalán.

ACAlejandro Corvalán
Alejandro CorvalánMDMD with degrees from Universidad de Chile and ECFMG certification; previously worked as a pathologist at Mount Sinai School of Medicine and postdoctoral fellow in molecular pathology at Tokyo Medical and Dental School and Kagoshima University. Currently Full Professor and Principal Investigator at the Advanced Center for Chronic Diseases at Pontificia Universidad Católica de Chile, conducting translational research on gastric cancer molecular biology.
FAFernando Alarcon
Fernando AlarconMBAFernando Alarcon has a background in corporate finance and M&A advisory across Latin America, working on valuations, capital raises, and growth strategy in healthcare and pharma sectors. He is co-founder of Ilico Genetics, which develops a blood-based molecular test using methylated DNA markers to detect gastric cancer early in high-risk patients.
MJ
Maria Jose Maturana RojasNamed on SEC filing
AH
Alejandro Hernan Corvalan RodriguezNamed on SEC filing
FA
Fernando A Alarcon HardyNamed on SEC filing
MJMaria J. Maturana
Maria J. MaturanaMSc

Investors · 2

Also in the syndicate · 1

Life Science Greenhouse Investments

Funding

SEC filings, press & company announcements

$457.7K disclosed across 1 of 2 rounds · 2023

  • Undisclosed amountSAFE roundSep 2023

    Life Science Greenhouse Investments

    Source ↗
▶$457.7KraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maria Jose Maturana RojasDirector
  • Alejandro Hernan Corvalan RodriguezDirector
  • Fernando A Alarcon HardyExecutive Officer, Director
Amount sold
$457.7K
Proceeds to insiders
$75K
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Ilico Genetics do?
Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.
Who founded Ilico Genetics?
Ilico Genetics was founded by Alejandro Corvalán in 2020.
Who are Ilico Genetics's investors?
Ilico Genetics's investors include Life Sciences Greenhouse Investments.
How much funding has Ilico Genetics raised?
Ilico Genetics has disclosed $457.7K raised across 1 of its 2 known rounds.
Where is Ilico Genetics headquartered?
Ilico Genetics is headquartered in Santiago, CL.